Developing a fast-acting antidote for methamphetamine overdose
Clinical Development of a Therapeutic Agent for Rapid Reversal of Methamphetamine Intoxication
This study is testing a new treatment called CS-1103 that helps quickly remove methamphetamine from the body, making it safer for people who have overdosed on the drug, and it's aimed at helping emergency departments handle these situations better.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clear Scientific, LLC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-10907555 on NIH RePORTER |
What this research studies
This research focuses on creating a new therapeutic agent, CS-1103, designed to rapidly reverse the effects of methamphetamine intoxication. The approach involves a small-molecule sequestrant that binds to methamphetamine in the bloodstream, facilitating its removal from the body through urine. The research aims to complete Phase 1b clinical trials to evaluate the safety and effectiveness of CS-1103 in humans, following promising results in animal studies. This could provide a critical solution for emergency departments dealing with methamphetamine overdoses.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced acute methamphetamine intoxication and require emergency medical intervention.
Not a fit: Patients who have not used methamphetamine or are not experiencing intoxication will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a life-saving antidote for individuals experiencing methamphetamine intoxication.
How similar studies have performed: While the approach of using a sequestrant for drug reversal is novel, similar strategies have shown promise in other contexts, indicating potential for success.
Where this research is happening
Cambridge, United States
- Clear Scientific, LLC — Cambridge, United States (Active)
Researchers
- Principal investigator: Li, Xinhua — Clear Scientific, LLC
- Study coordinator: Li, Xinhua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.